This is a working overview of obesity research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-20 and is reviewed periodically as new material appears.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
== Function == The primary protein encoded by HTN3 is histatin 3. Histatins are a family of small, histidine-rich, salivary proteins, encoded by at least two loci (HTN3 and HTN1). Post-translational proteolytic processing results in many histatins: e.g., histatins 4-6 are derived from histatin 3 by proteolysis. Histatins 1 and 3 are primary products of HIS1(1) and HIS2(1) alleles, respectively. Histatins are believed to have important non-immunological, anti-microbial function in the oral cavity. Histatin 1 and histatin 2 are major wound-closing factors in human saliva.
On December 24, 1851, the largest fire in the library's history destroyed 35,000 books, two-thirds of the library's collection, and two-thirds of Thomas Jefferson's original transfer. Congress appropriated $168,700 to replace the lost books in 1852 but not to acquire new materials. (By 2008, the librarians of Congress had found replacements for all but 300 of the works that had been documented as being in Jefferson's original collection.) This marked the start of a conservative period in the library's administration by librarian John Silva Meehan and joint committee chairman James A. Pearce, who restricted the library's activities. Meehan and Pearce's views about a restricted scope for the Library of Congress reflected those shared by members of Congress. While Meehan was a librarian, he supported and perpetuated the notion that "the congressional library should play a limited role on the national scene and that its collections, by and large, should emphasize American materials of obvious use to the U.S. Congress." In 1859, Congress transferred the library's public document distribution activities to the Department of the Interior and its international book exchange program to the Department of State. During the 1850s, Smithsonian Institution librarian Charles Coffin Jewett aggressively tried to develop the Smithsonian as the United States national library. His efforts were rejected by Smithsonian secretary Joseph Henry, who advocated a focus on scientific research and publication.
=== Phase I - modification === In phase I, a variety of enzymes acts to introduce reactive and polar groups into their substrates. One of the most common modifications is hydroxylation catalysed by the cytochrome P-450-dependent mixed-function oxidase system. These enzyme complexes act to incorporate an atom of oxygen into nonactivated hydrocarbons, which can result in either the introduction of hydroxyl groups or N-, O- and S-dealkylation of substrates. The reaction mechanism of the P-450 oxidases proceeds through the reduction of cytochrome-bound oxygen and the generation of a highly-reactive oxyferryl species, according to the following scheme:
=== D11AH Agents for dermatitis, excluding corticosteroids === D11AH01 Tacrolimus D11AH02 Pimecrolimus D11AH03 Cromoglicic acid D11AH04 Alitretinoin D11AH05 Dupilumab D11AH06 Crisaborole D11AH07 Tralokinumab D11AH08 Abrocitinib D11AH09 Ruxolitinib D11AH10 Lebrikizumab D11AH11 Delgocitinib D11AH12 Nemolizumab QD11AH90 Oclacitinib QD11AH91 Lokivetmab QD11AH92 Ilunocitinib QD11AH93 Atinvicitinib
In spite of these warnings, the Luftwaffe did little to address this and treated the entire topic with some level of disdain. Their own radars were superior to CH in many ways, but had proven to be only marginally useful. During the Air Battle of the Heligoland Bight in 1939, a German Freya radar detected the raid while it was still an hour away from its target, yet had no way to report this to any of the fighter units that could intercept it. Getting the information from the radar to the pilots in a useful form appeared to be a difficult problem, and the Germans believed the British would have the same difficulty and thus radar would have little real effect. Some desultory effort was put into attacking the CH stations, especially during the opening stages of the Battle. British engineers were able to quickly return these units to service, or in some cases simply pretend to do so in order to fool the Germans into thinking the attacks failed. As the pattern of these attacks became clear, the RAF began to counter them with increasing effectiveness. The Junkers Ju 87 dive bombers were subjected to catastrophic losses and had to be withdrawn from battle. The Germans gave up trying to attack CH directly on any reasonable scale. Thus, CH was allowed to operate throughout the Battle largely unhindered. Although communications were indeed a serious problem, it was precisely this problem that the Dowding system had been set up to address, at great expense. The result was that every British fighter was roughly twice or perhaps more as effective than its German counterpart.
Sources: en.wikipedia.org
=== By Dyson === Freeman Dyson at The New York Review of Books (content for subscribers only) "Heretical thoughts about science & society", essay by Freeman Dyson [8.7.2007] Templeton Prize acceptance lecture 2000, by Freeman Dyson Imagined Worlds by Freeman Dyson, 1996: Chapter 1 Video Interview of Freeman Dyson discussing Bogus Climate Models on YouTube A radio interview with Freeman Dyson Archived 7 August 2020 at the Wayback Machine Aired on the Lewis Burke Frumkes Radio Show in 2009. Suzan Mazur interviewing Dyson, 2012, CounterPunch "Pushing the Boundaries – A Conversation with Freeman Dyson" Archived 17 August 2016 at the Wayback Machine, Ideas Roadshow, 2014 Freeman Dyson and Gregory Benford: Forseeing the Next 35 Years – Where Will We Be in 2054? on YouTube, Arthur C. Clarke Center for Human Imagination, February 2019. A 'Rebel' Without a Ph.D.
== Prevention == Attacks of DKA can be prevented in those known to have diabetes to an extent by adherence to "sick day rules"; these are clear-cut instructions to patients on how to treat themselves when unwell. Instructions include advice on how much extra insulin to take when sugar levels appear uncontrolled, an easily digestible diet rich in salt and carbohydrates, means to suppress fever and treat infection, and recommendations on when to call for medical help. People with diabetes can monitor their own ketone levels when unwell and seek help if they are elevated.
== Fungus-derived == Edible mushrooms Mycoprotein – a form of single-cell protein, also known as fungal protein, it is able to provide greater satiety than traditional protein sources such as chicken, while also being rich in protein and low in caloric content Fistulina hepatica – a common mushroom known as beefsteak fungus Fusarium venenatum – a microfungus of the genus Fusarium that has a high protein content Hericium erinaceus – also known as lion's mane mushroom and has been explored as a steak alternative Laetiporus – a mushroom which is also named chicken of the woods Lyophyllum decastes – a mushroom known as fried chicken mushroom Neurospora crassa – a type of red bread mold of the phylum Ascomycota Pleurotus ostreatus – better known as the oyster mushroom, famous in the vegan community as one of the best substitutes for fried chicken
==== United States ==== As of 2018, Zipline was working with the FAA to develop rules for drone operation beyond the line of sight. During the COVID-19 pandemic in 2020, the FAA granted a Part 107 waiver to Novant Health in partnership with Zipline for the delivery of medical supplies and personal protective equipment to facilities in North Carolina. The company plans to offer deliveries to homes. On November 18, 2021, Zipline started a trial service with Walmart for e-commerce shopping deliveries in Pea Ridge, Arkansas. The service, selectable to online shoppers using a special mobile app, could deliver to all residences within 50 miles (80 km) of a particular Walmart store in Pea Ridge during daylight hours. On June 21, 2022, the license "Package Delivery by Drone (Part 135)" was granted. On October 4, 2022, Zipline began commercial delivery services in Salt Lake City, Utah, in partnership with Intermountain Healthcare. On September 18, 2023, the FAA announced it had authorized Zipline to begin making commercial deliveries beyond the line of sight without visual observers. In April 2025, Zipline began making deliveries for Walmart in the Dallas–Fort Worth metroplex using Platform 2 drones.
Sources: en.wikipedia.org
=== International relations === Marxism–Leninism aims to create an international communist society. It opposes colonialism and imperialism and advocates decolonisation and anti-colonial forces. It supports anti-fascist international alliances and has advocated the creation of popular fronts between communist and non-communist anti-fascists against strong fascist movements. This Marxist–Leninist approach to international relations derives from the analyses (political, economic, sociological and geopolitical) that Lenin presented in the essay Imperialism, the Highest Stage of Capitalism (1917). Extrapolating from five philosophical bases of Marxism, namely that human history is the history of class struggle between a ruling class and an exploited class; that capitalism creates antagonistic social classes, i.e.
It has been shown that approximately one-third of marathon runners experience dilation of the right atrium and ventricle, have elevations of cardiac troponin and natriuretic peptides, and in a smaller fraction later develop small patches of cardiac fibrosis that are the likely substrate for ventricular tachyarrhythmias and sudden death." A simple memorial gathering was held at Colorado Chautauqua in Boulder on April 6, in which friends ran up Flagstaff Mountain in Colorado and assembled on the Chautauqua park lawn to swap stories and remembrances of him. Due to True's role in the organization and production of the Copper Canyon Ultramarathon, after his death the continuation of the event was placed in doubt. The charitable organization, Norawas de Raramuri (Friends of the Running People), founded in 2009 by (in alphabetical order) Brooke Cantor, Deborah K. Kelly, Andrew Labbe, and Chris Labbe, continued to fund Rarámuri participation in the race. Between 2009 and 2013, Norawas de Rarámuri (501(c)(3)), raised and distributed approximately $40K per year, exclusively to Rarámuri communities, including exclusively Rarámuri events, other than the Copper Canyon Ultramarathon. Under new direction by Maria Walton, True's partner, and Fuego y Agua Events LLC. Director Josue Stephens, the race event continued for several more years. In honor of Micah, the race has since taken the name by which it has always been known in Mexico, Ultramaraton Caballo Blanco.
=== Road paving === Asphalt modification through nanoparticles can be considered as an interesting low-cost technique in asphalt pavement engineering providing novel perspectives in making asphalt materials more durable.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.